On December 15, 2025, Cofactor Genomics announced strategic investments from Labcorp and Ascension Ventures. The company said the funding is intended to expand its predictive immunotherapy diagnostic portfolio, generate clinical evidence, integrate with health systems, and scale commercial and laboratory operations. The announcement did not disclose investment amounts, ownership stakes, or specific rollout dates.
What is OncoPrism?
OncoPrism is a provider-ordered, RNA-based laboratory-developed diagnostic. Cofactor says it analyzes RNA from a patient’s tumor to estimate the likelihood of response to immune checkpoint inhibitor (ICI) therapy. Its technology uses immune profiling and machine-learning-based predictive modeling to produce a response score from formalin-fixed, paraffin-embedded (FFPE) solid-tumor tissue. It is not a consumer test or a general cancer screening test. Cofactor’s OncoPrism product page and technology page describe the test and its intended role.
What did Labcorp and Ascension Ventures invest in?
Cofactor’s December 15, 2025 announcement names Labcorp and Ascension Ventures as strategic investors and says their investments are intended to accelerate U.S. expansion and broaden patient access to OncoPrism. It identifies four areas the proceeds are intended to support:
- Expanding Cofactor’s predictive immunotherapy diagnostic portfolio
- Generating clinical evidence
- Integrating with health systems
- Scaling commercial and laboratory operations
These are announced plans, not evidence that new services or integrations are already in place. The release does not state the investment amounts, the investors’ ownership stakes, or a detailed implementation schedule. The announcement, distributed by Business Wire and syndicated by Yahoo Finance, describes Ascension Ventures as the strategic investment arm of 13 U.S. health systems across 22 states.
Do these 3 things before closing this tab:
1Clear out junk files and repair common Windows errors2Fix the driver behind crashes, sound loss and screen glitches3Repair Windows errors before they cause bigger problems#1 Best Overall
- PLAN FOR JOY AS EARLY AS 6 WEEKS: Experience the joy of learning the predicted sex of your baby as early as 6 weeks into pregnancy with the SneakPeek test advanced DNA-based testing. Our easy, at-home test kit is over 99% accurate and virtually pain-free, without the need for a doctor's visit, making it a perfect addition to your pregnancy announcement must-haves.
- #1 OBGYN-RECOMMENDED EARLY GENDER TEST: Backed by clinical research and on the list of top pregnancy must-haves, the SneakPeek baby early gender reveal test has been chosen by over 1 million parents-to-be. The test is the best way to celebrate your upcoming joy with over 99% accuracy – if the sex of your newborn doesn’t match your test result, you’ll receive a 100% refund of your purchase price.
- VIRTUALLY PAIN-FREE EXPERIENCE: Learning if you are likely to have a boy or girl has never been easier or more comfortable. SneakPeek Snap, our innovative, virtually pain-free arm collection method, is designed for your comfort with microneedles the width of a human hair. It replaces the traditional fingerstick for a virtually painless experience.
- RESULTS IN DAYS: Receive your baby's gender reveal as soon as the day after we receive your sample with SneakPeek Standard, and as soon as the same day we receive your sample with SneakPeek FastTrack! Our lab processes your sample with speed and precision. All lab costs are included, ensuring a seamless and joyful experience.
- EARLY DNA TESTING: While every person has their own DNA in their bloodstream, a pregnant person’s bloodstream also contains DNA from their unborn child. The SneakPeek test looks for Y chromosomes in a small sample of blood. If Y chromosomes are found that means baby is predicted to be a boy. If none are found, baby is predicted to be a girl.
Cofactor CEO Chris Parker said, “This is a major step in ensuring that every patient—regardless of treatment location—has access to a predictive diagnostic that can guide the use of immunotherapy.” Labcorp Vice President of New Ventures and Strategic Alliances Megann Vaughn Watters said, “Labcorp is committed to advancing precision oncology by delivering innovative diagnostics that empower clinicians with enhanced actionable insights.” Ascension Ventures Senior Managing Director John Kuelper said, “We partner with companies that can meaningfully impact care delivery across our health system partners.”
How could the investment expand access?
The announcement points to complementary networks: Labcorp’s national diagnostic network and Ascension Ventures’ relationships with health systems could help support broader access. That provides a rationale for the investment, but the release does not identify specific hospitals, laboratories, referral arrangements, or launch dates. It also does not establish that every Labcorp or Ascension-affiliated location will offer the test.
Rank #2
- ABOUT THE TEST: The Genetrace DNA Paternity Test helps families conclusively determine if a man is the true father of a child.
- NO HIDDEN FEES: Kit includes all lab fees and sample return costs to test one (1) child and one (1) potential father.
- FAST RESULTS: Get secure, confidential results within 1-2 business days after testing begins. We'll keep you updated every step of the way.
- EASY SAMPLE COLLECTION: No needles, no blood, no doctors. Collect your samples with our easy-to-use mouth swabs, then return them to the lab with the provided prepaid return envelope. It's quick, easy & painless.
- ACCURATE & RELIABLE: Up to 27 genetic markers analyzed for over 99.999% accuracy. All tests performed TWICE in our AABB, ISO 17025 & CLIA accredited laboratory.
For context, Labcorp’s Venture Fund page reports that 60%+ of its portfolio companies collaborate with Labcorp beyond investment, 85+ total direct investments, and $300M+ deployed since 2012. These figures describe the fund overall, not a Cofactor-specific partnership commitment. Labcorp Venture Fund
Which cancers does OncoPrism cover?
Cofactor’s current product page identifies recurrent or metastatic head and neck squamous cell carcinoma (RM-HNSCC) and non-small cell lung cancer (NSCLC) as validated uses. Its report description refers to anti-PD-1 response categories and fusion findings. These are company-described uses and report features; they do not mean the assay screens for cancer generally or applies to every cancer type. Cofactor’s product information
Rank #3
- Spin Columns extraction method
- DNA isolated from various samples
- Extration take less than 20 min
- Store Protease K and RNase A at 2~8℃
How is the OncoPrism test ordered?
Cofactor says a clinician orders the test through its provider access channels. The company works with the pathology department to obtain an existing tumor specimen rather than asking patients to order a kit. Cofactor says it returns a report within approximately two weeks after the specimen reaches its laboratory. OncoPrism-HNSCC is described as available to select health systems through an early-access program, so availability may depend on the institution and indication.
Cofactor states that OncoPrism has national Medicare coverage through Palmetto GBA. That statement does not establish coverage by every payer, coverage for every indication, or a particular patient’s out-of-pocket cost. Patients and clinicians should confirm current access, coverage, and any expected cost with Cofactor and the relevant payer before testing.
Rank #4
- Cost-effective and non-invasive method for capturing DNA samples
- 2ml saliva stabilization buffer to preserve integrity of DNA
- Standardized for high throughput processing
- Easy handling
- Efficient
Is OncoPrism FDA approved?
No. Cofactor describes OncoPrism as an NGS-based laboratory-developed test developed and characterized in a CLIA-regulated laboratory, and states that it has not been cleared or approved by the U.S. Food and Drug Administration. Cofactor also says results are not prescriptive or conclusive for the labeled use of a specific therapeutic product. The response score is therefore information for a clinician to consider, not a treatment directive or guarantee of response. Cofactor’s product page
What the announcement does—and does not—establish
The investment announcement establishes that Labcorp and Ascension Ventures are backing Cofactor’s stated expansion plans. It does not establish the amount or terms of either investment, a specific deployment timeline, or a head-to-head clinical advantage over other diagnostics. Cofactor presents comparative performance claims on its product page, but those claims alone are not enough to conclude that OncoPrism is superior to alternatives. A meaningful comparison would require details such as the tested populations, endpoints, specimen and workflow requirements, access and coverage, and regulatory status.
Recommended Free Tools
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
